ETF Data
ARKG ETF Data
Fund Profile · Snapshot Metrics · Exposure · Technicals · Risk
ARKG
ETF DataETF Data Overview
ETF pages show fund-native profile, cost, size, liquidity, exposure, technical, and risk evidence.
ETF Snapshot Data
Updated Sep 4, 2026.
| Field | Value |
|---|---|
| Fund name | ARK Genomic Revolution ETF |
| Issuer | ARK |
| Asset class | Equity |
| Primary exposure | Cash & Others (0.39%) |
| Domicile | US |
| Inception date | Oct 31, 2014 |
| NAV currency | USD |
| CUSIP | 00214Q302 |
| ISIN | US00214Q3020 |
| Field | Value |
|---|---|
| Price | $47.14 |
| Fund size | $1.56B |
| Expense ratio | 0.75% |
| Holdings count | 10 |
| NAV | $47.11 |
| Average volume | 2.59M |
| Distribution yield | 0.00% |
| AIQ Score | 52/100 |
ETF Holdings
Reported holdings from the latest ETF holder snapshot.
| Symbol | Holding | Weight | Market value |
|---|---|---|---|
| TXG | 10X GENOMICS INC-CLASS A | 9.52% | $191.31M |
| TWST | TWIST BIOSCIENCE CORP | 8.27% | $166.13M |
| TEM | TEMPUS AI INC-CL A | 8.10% | $162.69M |
| CRSP | CRISPR THERAPEUTICS AG | 6.04% | $121.35M |
| PSNL | PERSONALIS INC | 5.79% | $116.42M |
| ABSI | ABSCI CORP | 4.75% | $95.36M |
| GH | GUARDANT HEALTH INC | 4.30% | $86.47M |
| ILMN | ILLUMINA INC | 4.18% | $83.99M |
| NTRA | NATERA INC | 4.13% | $82.87M |
| LLY | ELI LILLY & CO | 3.86% | $77.53M |
| CDNA | CAREDX INC | 3.82% | $76.84M |
| BEAM | BEAM THERAPEUTICS INC | 3.56% | $71.52M |
| CMPS | COMPASS PATHWAYS PLC | 3.11% | $62.49M |
| RXRX | RECURSION PHARMACEUTICALS-A | 2.46% | $49.42M |
| SDGR | SCHRODINGER INC | 2.37% | $47.62M |
| WGS | GENEDX HOLDINGS CORP | 2.30% | $46.12M |
| ADPT | ADAPTIVE BIOTECHNOLOGIES | 2.29% | $45.93M |
| ARCT | ARCTURUS THERAPEUTICS HOLDIN | 2.24% | $44.92M |
| NRIX | NURIX THERAPEUTICS INC | 2.23% | $44.86M |
| VCYT | VERACYTE INC | 2.16% | $43.41M |
| NTLA | INTELLIA THERAPEUTICS INC | 1.83% | $36.76M |
| BFLY | BUTTERFLY NETWORK INC | 1.82% | $36.63M |
| IONS | IONIS PHARMACEUTICALS INC | 1.78% | $35.76M |
| ALMR | ALAMAR BIOSCIENCES INC | 1.53% | $30.82M |
| PRME | PRIME MEDICINE INC | 1.46% | $29.36M |
ETF Exposure
Sector and country composition fields from ETF snapshots where available.
| Field | Value |
|---|---|
| Cash & Others | 0.39% |
| Healthcare | 97.20% |
| Technology | 2.41% |
| Field | Value |
|---|---|
| United States | 88.44% |
| Switzerland | 6.14% |
| United Kingdom | 3.20% |
| Other | 2.23% |
Institutional Holder Snapshot
Latest downstream filing-reported holders and share-count changes for this ETF.
| Holder | Shares | Change | Reported |
|---|---|---|---|
| MORGAN STANLEY | 6.72M | 1.87M | Jun 30, 2026 |
| MORGAN STANLEY | 6.72M | 1.87M | Jun 30, 2026 |
| Jefferies Financial Group Inc. | 1.8M | 1.05M | Jun 30, 2026 |
| Jefferies Financial Group Inc. | 1.8M | 1.05M | Jun 30, 2026 |
| UBS Group AG | 1.59M | 678.76K | Jun 30, 2026 |
| CITADEL ADVISORS LLC | 0 | -294.16K | Jun 30, 2026 |
| CITADEL ADVISORS LLC | 0 | -294.16K | Jun 30, 2026 |
| GFS Advisors, LLC | 0 | -186.81K | Jun 30, 2026 |
| GFS Advisors, LLC | 0 | -186.81K | Jun 30, 2026 |
| Walleye Trading LLC | 0 | -70.99K | Jun 30, 2026 |
Current ETF Metrics
ETF-native fields sit beside technical and risk readings for deeper research.
| Metric | Value | Unit | As of |
|---|---|---|---|
| Expense Ratio | 0.75 | percent | Sep 4, 2026 |
| Fund Size | 1,557,000,000 | currency | Sep 4, 2026 |
| Nav | 47.11 | currency_per_share | Sep 4, 2026 |
| Average Volume | 2,594,209 | count | Sep 4, 2026 |
| Distribution Yield | — | percent | Sep 4, 2026 |
| Beta | 2.38 | ratio | Sep 4, 2026 |
| High52 | — | currency_per_share | Sep 4, 2026 |
| Low52 | — | currency_per_share | Sep 4, 2026 |
| Metric | Value | Unit | As of |
|---|---|---|---|
| Close | 47.14 | price | Sep 4, 2026 |
| Volume | 1,446,207 | volume | Sep 4, 2026 |
| Rsi14 | 60.18 | index | Sep 4, 2026 |
| MACD | 1.63 | index | Sep 4, 2026 |
| MACD Signal | 1.95 | index | Sep 4, 2026 |
| MACD Histogram | -0.32 | index | Sep 4, 2026 |
| Adx14 | 34.23 | index | Sep 4, 2026 |
| Sma50 | 43 | price | Sep 4, 2026 |
| Sma200 | 33.41 | price | Sep 4, 2026 |
| Atr14 | 1.64 | price | Sep 4, 2026 |
| Historical Volatility | 0.5 | percent | Sep 4, 2026 |
| Volume Ma20 | 4,121,265.95 | volume | Sep 4, 2026 |
| Metric | Value | Unit | As of |
|---|---|---|---|
| Resilience Score | 10 | score_0_100 | Sep 4, 2026 |
| Beta | 2.38 | ratio | Sep 4, 2026 |
| Volatility Annual | 45.02 | percent | Sep 4, 2026 |
| Max Drawdown | -27.51 | percent | Sep 4, 2026 |
| Sharpe Ratio | 1.56 | ratio | Sep 4, 2026 |
| Var95 | -3.95 | percent | Sep 4, 2026 |
Additional ETF Metrics
Expanded ETF structure fields appear here when the entitlement and source coverage allow them.
No additional ETF structure metrics are available.
Related Links
ARKG ETF Data FAQ
What is ARK Genomic Revolution ETF's revenue?
ARK Genomic Revolution ETF's revenue is one of the core financial data points for ARKG. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.
Is ARK Genomic Revolution ETF's revenue growing?
Revenue growth shows whether ARK Genomic Revolution ETF is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.
What is ARKG's EPS?
ARKG's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.
What is ARK Genomic Revolution ETF's net income?
ARK Genomic Revolution ETF's net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.
How much free cash flow does ARK Genomic Revolution ETF generate?
Free cash flow shows how much cash ARK Genomic Revolution ETF generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.
How much cash and debt does ARK Genomic Revolution ETF have?
Cash and debt help frame ARKG's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.